


Miltenyi Biotec strengthens its research capabilities for cell analysis and preclinical imaging by acquiring a MILabs' premium Optical/CT imaging system



September 9, 2020, Utrecht, The Netherlands and Bergisch Gladbach, Germany

Miltenyi Biotec B.V. & Co. KG, a global provider of products and services for advancing biomedical research and cellular therapy, and MILabs B.V. announced today that Miltenyi has acquired a high-end MILabs VECTor OI/CT system. This hybrid Optical Imaging with in-line X-ray CT comes with a unique Duet Optical docking station so that both high-throughput 2D optical imaging as well as CT-guided 3D optical tomography of deep tissue can be performed. Moreover, the X-ray CT system enables diagnostic imaging including high-resolution soft-tissue visualization with contrast agents.



“We are excited to add this advanced hybrid Optical/CT preclinical imaging system to our research platform” says Dr. Wa’el Al Rawashdeh, Ph.D, Group Leader Preclinical Studies and Cell Tracking at Miltenyi Biotec. “By combining our expertise in cell analysis and innovative detection reagents and technologies we will be able to exploit MILabs’ VECTor OI/CT exclusive imaging capabilities to further develop pioneering tools and reagents for biomedical research, in particular cell and gene therapy, as well as preclinical and clinical cell-therapy tracking technologies”.

“Our mission has always been to develop and market new preclinical imaging technologies such as our hybrid 2D/3D Optical/CT system” explains Prof. Frederik Beekman, CEO/CSO of MILabs

B.V. We are grateful that Miltenyi Biotec, which has extensive expertise in developing both optical and X-ray CT probes and contrast agents, has selected MILabs as its supplier for preclinical imaging products”.

About Miltenyi Biotec B.V. & Co. KG:

Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. Used by scientists and clinicians around the world, our technologies enable solutions for cellular research, cell therapy, cell manufacturing, and imaging. Our 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer. Today, Miltenyi Biotec has more than 3,000 employees in 28 countries – all dedicated to helping researchers and clinicians make a greater impact on science and health. www.miltenyibiotec.com

About MILabs B.V.:

This fast-growing Dutch company has a history of providing a continuum of innovations to expand the applications preclinical molecular imaging. With its latest adaptive platform, MILabs has succeeded at commercializing a scalable imaging platform, able to accommodate Optical and CT imaging as well as the nuclear PET and SPECT techniques. MILabs has built a strong brand based on its mission of “Making Molecular Imaging Clear”. With ultra-high-resolution and multiparametric imaging complemented by theranostic capabilities, it provides efficient translational systems for both diagnostic and therapy applications. For more information, visit: www.milabs.com or contact MILabs at info@milabs.com